We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why is Juno Therapeutics (JUNO) Stock Plunging 31% Today?
Read MoreHide Full Article
On Friday, shares of biopharmaceutical company Juno Therapeutics Inc. are plunging, down around 31% as of 10:36 AM EST after three patients died in a trial for its leading cancer therapy. The U.S. Food and Drug Administration has put the study on hold.
The study was a Phase II clinical trial of JCAR015, otherwise known as the “ROCKET” trial, in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), a cancer that affects the immune system. Two patients died last week after fludarabine, a chemotherapy drug, was added to the treatment. Another patient, who received the same fludarabine additive, died at the end of May.
In response, Juno has suggested to the FDA that the ROCKET trial should continue, using only the cyclophosphamide pre-conditioning with JCAR015. The FDA, however, wants Juno to submit a revised patient informed consent form, a revised investigator brochure, a revised trial protocol, and a presentation copy made to the agency yesterday.
Juno is expected to submit these revised documents this week.
The news has not been kind to other biopharmaceutical companies.
Kite Pharma Inc. , a clinical-stage biopharmaceutical company that focuses on development of cancer immunotherapy products, saw its stock fall over 8% in morning trading, and Bluebird Bio Inc. (BLUE - Free Report) , a biotech company that develops therapies for severe genetic disorders, dropped 2% in morning trading, but has recovered slightly.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Why is Juno Therapeutics (JUNO) Stock Plunging 31% Today?
On Friday, shares of biopharmaceutical company Juno Therapeutics Inc. are plunging, down around 31% as of 10:36 AM EST after three patients died in a trial for its leading cancer therapy. The U.S. Food and Drug Administration has put the study on hold.
The study was a Phase II clinical trial of JCAR015, otherwise known as the “ROCKET” trial, in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), a cancer that affects the immune system. Two patients died last week after fludarabine, a chemotherapy drug, was added to the treatment. Another patient, who received the same fludarabine additive, died at the end of May.
In response, Juno has suggested to the FDA that the ROCKET trial should continue, using only the cyclophosphamide pre-conditioning with JCAR015. The FDA, however, wants Juno to submit a revised patient informed consent form, a revised investigator brochure, a revised trial protocol, and a presentation copy made to the agency yesterday.
Juno is expected to submit these revised documents this week.
The news has not been kind to other biopharmaceutical companies.
Kite Pharma Inc. , a clinical-stage biopharmaceutical company that focuses on development of cancer immunotherapy products, saw its stock fall over 8% in morning trading, and Bluebird Bio Inc. (BLUE - Free Report) , a biotech company that develops therapies for severe genetic disorders, dropped 2% in morning trading, but has recovered slightly.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>